Compound research
What is retatrutide in the published literature?
Retatrutide is described in the literature as an investigational peptide agonist of the GIP, GLP-1, and glucagon receptors. The references below establish research identity and study context; they do not establish the quality, safety, or intended use of any material sold by Astral.
Source trail
Selected references
Human phase 2 trial
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP, et al. New England Journal of Medicine (2023).
Defines the investigational triple-receptor agonist and its clinical research context; it is not evidence about Astral material.
Human phase 2a trial
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Sanyal AJ, Kaplan LM, Frias JP, et al. Nature Medicine (2024).
Reports a separate clinical research setting for the same investigational molecule; no product-quality inference is made.
How to interpret this page
These sources establish research context only. They do not verify an Astral lot, support dosing or human use, or prove safety or efficacy. Use the lot-specific COA for analytical evidence.
Editorially curated and source-verified; not independently peer-reviewed by Astral. Last source check: 2026-07-21. Read the editorial policy.